PCSK9 Inhibitor Very Effective in High‑Risk Patients Without ASCVD: VESALIUS‑CV

A prespecified subgroup analysis from the VESALIUS‑CV trial shows that adding the PCSK9 inhibitor evolocumab (Repatha) to statin therapy markedly reduces major cardiovascular events in high‑risk patients with diabetes but no established atherosclerotic cardiovascular disease (ASCVD). The findings, presented at the American College of Cardiology 2026 Scientific Session and published in JAMA, support using LDL targets typically reserved for secondary prevention—often below 55 mg/dL, and even near 40 mg/dL—for selected high‑risk primary‑prevention patients.

VESALIUS‑CV in high‑risk patients without ASCVD

VESALIUS‑CV enrolled 12,257 patients at high cardiovascular risk, including those with diabetes plus a risk enhancer or established atherosclerosis with elevated LDL‑C ≥ 90 mg/dL. In this subgroup, 3,355 patients had diabetes but no significant atherosclerosis, with a median baseline LDL‑C of about 121 mg/dL.

Over 48 weeks, evolocumab on top of statins cut LDL‑C by roughly half to a median of about 52 mg/dL, and by 96 weeks the LDL‑C in the evolocumab arm dropped to around 44 mg/dL. This produced a mean difference of nearly 60 mg/dL versus placebo‑added statin therapy.

At 5 years, evolocumab reduced three‑point MACE (coronary heart disease death, MI, or ischemic stroke) from 7.1% to 5.0%, an absolute reduction of 2.1%. The four‑point MACE endpoint, which added ischemia‑driven revascularization, fell from 10.5% to 7.6%, an absolute reduction of 2.9%. Both all‑cause and cardiovascular death were significantly lower in the evolocumab group.

How this fits the new dyslipidemia guidelines

The 2026 ACC/AHA dyslipidemia guidelines recommend an LDL‑C target of less than 100 mg/dL for patients with diabetes but no ASCVD and less than 70 mg/dL for those with diabetes plus multiple risk factors; the < 55 mg/dL target is reserved for very high‑risk patients with ASCVD. VESALIUS‑CV was published too late to be incorporated into those guidelines, but the writing committee acknowledged in an accompanying editorial that the trial supports more aggressive LDL‑C lowering in high‑risk individuals with diabetes even before ASCVD appears.

The current guideline framework favors high‑intensity statins, with ezetimibe if needed, and restricts PCSK9 inhibitors mainly to ASCVD patients on maximal oral therapy. In this subgroup, however, baseline LDL‑C was substantially higher than in trials like Ez‑PAVE, so even ezetimibe often would not bring many patients down to < 70 mg/dL, making PCSK9 inhibition a more powerful option.

Clinical takeaways for cardiologists

For the practicing cardiologist, VESALIUS‑CV suggests that high‑risk primary‑prevention patients with diabetes—especially those with long‑standing disease, hypertension, or multiple risk factors—may benefit from LDL‑C targets closer to or below 55 mg/dL, similar to strategies used in secondary prevention. Evolocumab added to statins achieves profound LDL‑C lowering and a robust reduction in first major cardiovascular events, supporting earlier intensification before atherosclerosis becomes clinically evident.

While ezetimibe remains a more cost‑effective first‑step add‑on, in patients with very high baseline LDL‑C who cannot reach < 70 mg/dL on statin plus ezetimibe, PCSK9 inhibitors may be the most practical way to deliver meaningful risk reduction. Community internists, endocrinologists, and cardiologists will need to collaborate closely, and broader payer coverage of PCSK9 inhibitors will likely grow as the data confirm that lower LDL‑C earlier translates into fewer first‑time MACE, even in patients without prior ASCVD.